Research ArticleArticle
Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11
Laura C. Coates, Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh and Philip S. Helliwell
The Journal of Rheumatology February 2014, jrheum.131250; DOI: https://doi.org/10.3899/jrheum.131250
Laura C. Coates
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Oliver FitzGerald
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Philip J. Mease
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Dafna D. Gladman
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Vibeke Strand
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Niti Goel
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Ina Campbell
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Gerald Krueger
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Neil J. McHugh
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Philip S. Helliwell
From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland; Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California; Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK. L.C. Coates, MBChB, MRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP(UK), Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin; P.J. Mease, MD, Seattle Rheumatology Associates, Director of Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D.D. Gladman, MD, FRCPC, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Strand, MD, FACP, FACR, Clinical Professor, Adjunct, Division of Immunology/Rheumatology, Stanford University; N. Goel, MD, FACR, Adjunct Assistant Professor of Medicine, Division of Rheumatology, Department of Medicine, Duke University Medical Center; General Medicine Therapeutic Delivery Unit, Quintiles; I. Campbell, BA, BEd, LLB, Patient Research Partner, Markham, Ontario, Canada; G. Krueger, MD, Department of Dermatology, University of Utah; N.J. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases and University of Bath; P.S. Helliwell, MA, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds. Address correspondence to Dr. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. E-mail: p.helliwell@leeds.ac.uk
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11
Laura C. Coates, Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh, Philip S. Helliwell
The Journal of Rheumatology Feb 2014, jrheum.131250; DOI: 10.3899/jrheum.131250
Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11
Laura C. Coates, Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh, Philip S. Helliwell
The Journal of Rheumatology Feb 2014, jrheum.131250; DOI: 10.3899/jrheum.131250